FDA Classifies New Tinnitus Stimulation Device
Published Date: 6/10/2026
Rule
Summary
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Device reclassified to Class II, speeding access
The FDA classified the combined acoustic and electrical external stimulation device for tinnitus as Class II (special controls), effective June 10, 2026, and applicable retroactively to March 6, 2023. FDA says this Class II classification reduces regulatory burdens compared with automatic Class III assignment and will enhance patients' access to this device.
Creates a predicate pathway for future devices
FDA's De Novo classification means this device type can serve as a predicate for future substantially equivalent devices, allowing other sponsors to use the less burdensome 510(k) premarket notification process instead of De Novo or premarket approval. The order explains that after classification into class I or II via De Novo, future device sponsors can rely on this device as a predicate.
Mandatory safety tests and prescriber-only labeling
The Class II order imposes special controls requiring clinical performance testing, non-clinical verification of electrical and acoustic parameters, electromagnetic compatibility and battery safety testing, software verification/validation and hazard analysis, biocompatibility of patient-contacting components, and human factors testing. Labeling must state that the device is intended to be prescribed by a healthcare professional with expertise in evaluation and management of tinnitus and must include device specifications (e.g., electrical output waveform, stimulation peak voltage and current, pulse duration, frequency, maximum current density, maximum phase charge, and power source).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-15187, Cancer Clinical Trial Eligibility Criteria: Laboratory Values; Guidance for Industry, Institutional Review Boards, and Clinical Investigators; Availability
The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance for industry, institutional review boards (IRBs), and clinical investigators entitled "Cancer Clinical Trial Eligibility Criteria: Laboratory Values." This guidance is one in a series of guidances that provide recommendations regarding eligibility criteria for clinical trials of investigational drugs regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation Research (CBER) for the treatment of cancer. Specifically, this guidance includes recommendations for selecting appropriate laboratory values as trial eligibility criteria to avoid unjustified exclusions of trial participants. This guidance finalizes the draft guidance of the same title issued on April 26, 2024.
2026-15185, Cancer Clinical Trial Eligibility Criteria: Performance Status; Guidance for Industry, Institutional Review Boards, and Clinical Investigators; Availability
The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance for industry entitled "Cancer Clinical Trial Eligibility Criteria: Performance Status." This guidance is one in a series of guidances that provide recommendations regarding eligibility criteria for clinical trials of investigational drugs regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation Research (CBER) for the treatment of cancer. Specifically, this guidance includes recommendations regarding expanding eligibility criteria to include patients with a wider range of performance status. This guidance finalizes the draft guidance of the same title issued on April 26, 2024.
2026-15186, Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications; Guidance for Industry, Institutional Review Boards, and Clinical Investigators; Availability
The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance for industry, institutional review boards (IRBs), and clinical investigators entitled "Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications." This guidance is one in a series of guidances that provide recommendations regarding eligibility criteria for clinical trials of investigational drugs regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation Research (CBER) for the treatment of cancer. Specifically, this draft guidance includes recommendations regarding the appropriate use of washout periods and concomitant medication exclusions. This guidance finalizes the draft guidance of the same title issued on April 26, 2024.
2026-15147, Fee Rate for Using a Priority Review Voucher in Fiscal Year 2026; Correction
The FDA fixed some details about the fee for using a Priority Review Voucher in 2026. If you're submitting a drug application using one of these special vouchers, you now have to pay the fee right when you submit your application. This change affects companies working on rare pediatric diseases, tropical diseases, or medical countermeasures, and it kicks in starting February 3, 2026.
Previous / Next Documents
Previous: 2026-11585, Penalty Inflation Adjustments for Civil Monetary Penalties
Starting June 10, 2026, the Social Security Administration is updating its civil penalty amounts to keep up with inflation. This means fines for breaking certain rules will be a bit higher to match today’s prices. If you deal with SSA rules, watch out—penalties are now adjusted every year to stay fair and current!
Next: 2026-11592, Publication of Cyber-Related Sanctions Regulations Web General License 2
The Treasury’s Office of Foreign Assets Control (OFAC) officially published General License 2, which lets certain water treatment and distribution transactions with Anco Water Supply Co. Ltd. happen, even though sanctions usually block them. This change helps companies involved in drinking water services keep things flowing smoothly without breaking the rules. The license took effect on April 23, 2026, so affected businesses should act now to stay compliant and avoid penalties.